Teva Pharmaceutical Industries (TEVA) Work In Process (2009 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Work In Process for 10 consecutive years, with $590.0 million the latest figure, recorded in Q4 2018.

• For the quarter ending Q4 2018, Work In Process fell 1.17% year-over-year to $590.0 million; the trailing twelve-month figure through Dec 2018 stood at $590.0 million (down 1.17% YoY), and the FY2018 full-year result was $590.0 million, down 1.17% from the prior year.
• Work In Process slipped to $590.0 million in Q4 2018 per TEVA's latest filing, from $609.0 million in the prior quarter.
• Across five years, Work In Process topped out at $734.0 million in Q2 2014 and bottomed at $475.0 million in Q2 2016.
• Historically, Work In Process has averaged $609.9 million across 5 years, with a median of $607.0 million in 2015.
• The sharpest annual moves came in 2016 and 2017: Work In Process declined 25.31% in 2016, then gained 27.37% in 2017.
• Over 5 years, Work In Process stood at $638.0 million in 2014, then slipped by 16.14% to $535.0 million in 2015, then rose by 0.56% to $538.0 million in 2016, then advanced by 10.97% to $597.0 million in 2017, then slipped by 1.17% to $590.0 million in 2018.
• According to Business Quant data, Work In Process over the past three periods registered $590.0 million, $609.0 million, and $605.0 million for Q4 2018, Q3 2018, and Q2 2018 respectively.